transmembrane protein 63AGenealiases: HLD19 · KIAA0792 · hTMEM63A
Q-omics provides the consensus-scored TMEM63A profile across patient tissues and cancer cell-line models. TMEM63A expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, TMEM63A is differentially expressed in 9, with the highest sampling consensus in COAD. Additionally, TMEM63A protein abundance shows 22,964 significant protein co-abundance associations, with the highest sampling consensus in LUAD. Together, these results highlight ACC, COAD, and LUAD as cancer lineages where TMEM63A shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TMEM63A — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TMEM63A survival associations across molecular data types. TMEM63A RNA expression shows survival associations in the most cancer types (25), followed by mutation status (2) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TMEM63A RNA expression–survival associations across cancer types. High TMEM63A expression shows unfavorable associations in ACC, MESO, UVM, CESC and THCA, but favorable associations in UCS. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for TMEM63A RNA expression.
This table summarizes TMEM63A tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9, while mass-spec protein shows differences in 6. The strongest signals are observed in COAD for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for TMEM63A. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TMEM63A shows lower tumor expression in KICH and LUSC and higher tumor expression in COAD, STAD, LIHC and LUAD. The COAD box plot shows higher TMEM63A RNA expression in tumor versus normal tissue (log2 FC = +1.695, t-test p < 0.001).
This table shows molecular features associated with TMEM63A in patient tissues and cancer cell lines. In patient samples, TMEM63A shows the broadest associations at the RNA and protein expression levels, with LUAD recurring as the lineage with the largest associated feature set. In cancer cell lines, TMEM63A RNA and mutation anchors are most strongly linked to RNA-expression features, especially in KIDNEY, while CRISPR and shRNA rows add functional-dependency signals in CNS and UPPER_AERODIGESTIVE_TRACT.
